Acasti Pharma Inc , a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases.
Acasti Pharma is a micro cap stock with a total market cap of 24.92M.
They trade on the NASDAQ and had their IPO 11 years and 4 months
Acasti Pharma currently employs 32 people.
News Relating to $ACST
Zacks Investment Research
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?
Tuesday Feb 28 2023 at 11:18
Here is how Acasti Pharma (ACST) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
Seeking Alpha
Acasti Pharma Inc. (ACST) Q3 2023 Earnings Call Transcript
Tuesday Feb 14 2023 at 15:53
Acasti Pharma Inc. (NASDAQ:ACST ) Q3 2023 Earnings Conference Call February 14, 2023 1:00 PM ET Company Representatives Jan D’Alvise – President, Chief Executive Officer Brian Ford – Chief Financial Officer Pierre Lemieux – Chief Operating and Scientific Officer, Co-Founder Prashant Kohli – Chief Commercial Officer Robert Blum – Lytham Partners Conference Call Participants Leland Gershell – Oppenheimer Oren Livnat – H.C. Wainwright Operator Good day, and welcome to the Acasti Pharma Reports Third Quarter of Fiscal Year 2023 Financial Results and Business Update Call.
GlobeNewsWire
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31
Tuesday Jan 24 2023 at 16:15
LAVAL, Québec, Jan. 24, 2023 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D’Alvise, CEO, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.
GlobeNewsWire
Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18
Friday Jan 13 2023 at 09:00
LAVAL, Québec, Jan. 13, 2023 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced Jan D’alvise, CEO, will present and host one-on-one meetings with investors at the Sidoti January Virtual Investor Conference, taking place on January 18-19, 2023.
GlobeNewsWire
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
Thursday Jan 05 2023 at 09:00
LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that it will host a conference call on Tuesday, January 10, 2023 at 4:30 p.m. ET to review the recently reported preliminary topline results from two separate Phase 1 pharmacokinetic (PK) studies for GTX-101 and GTX-102. Both studies successfully met all target outcome measures.
PennyStocks
Best Penny Stocks To Buy Now? 4 Stocks Under $4 To Watch
Wednesday Dec 28 2022 at 13:16
Penny stocks to watch this week. The post Best Penny Stocks To Buy Now?
Seeking Alpha
Acasti Pharma Inc. (ACST) Q2 2023 Earnings Call Transcript
Monday Nov 14 2022 at 23:23
Acasti Pharma Inc. (NASDAQ:ACST ) Q2 2023 Earnings Conference Call November 14, 2022 1:00 PM ET Company Participants Robert Blum – Lytham Partners, IR Jan D’Alvise – President & CEO Brian Ford – CFO Prashant Kohli – Chief Commercial Officer Conference Call Participants Leland Gershell – Oppenheimer Sahil Kazmi – B. Riley Securities Operator Good day, and welcome to the Acasti Pharma Second Quarter 2023 Earnings Event Call.
GlobeNewsWire
Acasti Pharma to Present at Q4 Investor Summit
Wednesday Nov 09 2022 at 16:15
LAVAL, Québec, Nov. 09, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announced that Jan D’Alvise, President and CEO of Acasti Pharma will be presenting virtually at the Q4 Investor Summit. The Company will be conducting a webcasted presentation and participating in one-on-one meetings with investors.
GlobeNewsWire
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022
Monday Nov 07 2022 at 16:15
Call to be held on Monday, November 14th at 1:00 PM Eastern Time Call to be held on Monday, November 14th at 1:00 PM Eastern Time
GlobeNewsWire
Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference
Wednesday Sep 14 2022 at 16:15
LAVAL, Québec, Sept. 14, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announced today that it will be participating in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.
Insider Trading
Data is unavailable for Insider Trading
Debt & Income Analysis
(Original Source: SEC.GOV)
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
$ACST’s Income Quality of 0.91 is greater than its Industry Group of 0.8 (13.7% greater)
$ACST’s Income Quality of 0.91 is greater than its Major Industry Group of 0.81 (12.3% greater)
$ACST’s Income Quality of 0.91 is in line with its Sector of 0.83 (9.6% greater)
(Original Source: SEC.GOV)
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
$ACST’s Current Ratio of 9.86 is greater than its Industry Group of 4.51 (118.6% greater)
$ACST’s Current Ratio of 9.86 is greater than its Major Industry Group of 4.13 (138.7% greater)
$ACST’s Current Ratio of 9.86 is greater than its Sector of 2.48 (297.6% greater)
Value Analysis
(Original Source: SEC.GOV)
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Cannot compare a negative PE Ratio (-1.44 & -1.4)
Cannot compare a negative PE Ratio (-1.44 & -1.22)
Cannot compare a negative PE Ratio (-1.44 & -0.12)
(Original Source: SEC.GOV)
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
$ACST’s PB Ratio of 0.24 is lower than its Industry Group of 1.39 (-82.7% lower)
$ACST’s PB Ratio of 0.24 is lower than its Major Industry Group of 1.47 (-83.7% lower)
$ACST’s PB Ratio of 0.24 is lower than its Sector of 1.7 (-85.9% lower)
Efficiency Analysis
(Original Source: SEC.GOV)
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
$ACST’s ROE of -0.17 is greater than its Industry Group of -0.47 (63.8% greater)
$ACST’s ROE of -0.17 is greater than its Major Industry Group of -0.41 (58.5% greater)
Cannot compute a percentage difference when there are zeros in the calculation
(Original Source: SEC.GOV)
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
$ACST’s ROCE of -0.16 is greater than its Industry Group of -0.43 (62.8% greater)
$ACST’s ROCE of -0.16 is greater than its Major Industry Group of -0.38 (57.9% greater)
$ACST’s ROCE of -0.16 is lower than its Sector of 0.01 (-1700.0% lower)